TickerFacts.

Neuraxis, Inc (NRXS): Capital Expenditures

Annual figures by period end, from SEC filings.

$31.1K
Year ended 2025-12-31
$12.2K
Trailing 12 months to 2026-06-30
+181.9%
3-year compound annual growth
2022-12-31: $1.4K2023-12-31: $30.8K2024-12-31: $27.8K2025-12-31: $31.1K$31.1K
2022-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$31.1K+12.1%2026-03-19, From 2025-01-01
2024-12-31$27.8K-9.8%2026-03-19, From 2024-01-01
2023-12-31$30.8Kn/m2025-03-20, From 2023-01-01
2022-12-31$1.4Kn/a2024-04-16, From 2022-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Electromedical & Electrotherapeutic Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Neuraxis, Inc (NRXS)2025-12-31$31.1K+12.1%
Hongchang International Co., Ltd (HCIL)2024-12-31$4.02M-90.1%
Nuwellis, Inc. (NUWE)2025-12-31$90.0K+50.0%
Escalon Medical Corp (ESMC)2025-06-30$3.9K-90.4%
CapsoVision, Inc (CV)2025-12-31$90.0K-41.2%
Hyperfine, Inc. (HYPR)2025-12-31$1.19M+209.4%
Guided Therapeutics Inc (GTHP)2025-12-31$2.0Kn/a
QT Imaging Holdings, Inc. (QTI)2025-12-31$124.0K+40.9%
Precision Optics Corporation, Inc. (POCI)2025-06-30$227.2K-16.6%

Compare NRXS, HCIL, NUWE, ESMC side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗